hormonal therapies

R&D

Irina Spirieva started her career in fast-moving consumer goods working in brand management for AB-InBev and Heineken.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.